Clinical characteristics of TFL cohort
| . | All TFL patients (n = 155) . | |
|---|---|---|
| . | (No.) . | (%) . |
| Year of FL diagnosis | ||
| <2003 | 104 | 67 |
| ≥2003 | 51 | 33 |
| Year of TFL diagnosis | ||
| <2003 | 59 | 38 |
| ≥2003 | 96 | 62 |
| Antecedent FL grade | ||
| Grade 1 or 2 | 135 | 87 |
| Grade 3A | 20 | 13 |
| Time to transformation (y) | ||
| ≤5 | 98 | 63 |
| 5-10 | 39 | 25 |
| >10 | 18 | 12 |
| Age at TFL diagnosis (y) | ||
| ≤60 | 65 | 42 |
| >60 | 90 | 58 |
| First line treatment of FL | ||
| Single-agent chemo | 34 | 24 |
| Multi-agent chemo* | 22 | 15 |
| Multi-agent chemo† + rituximab | 14 | 10 |
| Radiation or surgery | 21 | 15 |
| Observation | 52 | 36 |
| N/A | 12 | — |
| Initial treatment after transformation | ||
| Multi-agent chemo‡ | 46 | 32 |
| Multi-agent chemo§ + rituximab | 82 | 56 |
| Other | 18 | 12 |
| N/A | 9 | — |
| Hematopoietic stem cell transplant | ||
| Autologous | 12 | 8 |
| Allogeneic | 3 | 2 |
| None | 133 | 90 |
| N/A | 7 | — |
| Rituximab before transformation | ||
| No | 120 | 79 |
| Yes | 32 | 21 |
| N/A | 3 | — |
| Rituximab after transformation | ||
| No | 61 | 40 |
| Yes | 91 | 60 |
| N/A | 3 | — |
| . | All TFL patients (n = 155) . | |
|---|---|---|
| . | (No.) . | (%) . |
| Year of FL diagnosis | ||
| <2003 | 104 | 67 |
| ≥2003 | 51 | 33 |
| Year of TFL diagnosis | ||
| <2003 | 59 | 38 |
| ≥2003 | 96 | 62 |
| Antecedent FL grade | ||
| Grade 1 or 2 | 135 | 87 |
| Grade 3A | 20 | 13 |
| Time to transformation (y) | ||
| ≤5 | 98 | 63 |
| 5-10 | 39 | 25 |
| >10 | 18 | 12 |
| Age at TFL diagnosis (y) | ||
| ≤60 | 65 | 42 |
| >60 | 90 | 58 |
| First line treatment of FL | ||
| Single-agent chemo | 34 | 24 |
| Multi-agent chemo* | 22 | 15 |
| Multi-agent chemo† + rituximab | 14 | 10 |
| Radiation or surgery | 21 | 15 |
| Observation | 52 | 36 |
| N/A | 12 | — |
| Initial treatment after transformation | ||
| Multi-agent chemo‡ | 46 | 32 |
| Multi-agent chemo§ + rituximab | 82 | 56 |
| Other | 18 | 12 |
| N/A | 9 | — |
| Hematopoietic stem cell transplant | ||
| Autologous | 12 | 8 |
| Allogeneic | 3 | 2 |
| None | 133 | 90 |
| N/A | 7 | — |
| Rituximab before transformation | ||
| No | 120 | 79 |
| Yes | 32 | 21 |
| N/A | 3 | — |
| Rituximab after transformation | ||
| No | 61 | 40 |
| Yes | 91 | 60 |
| N/A | 3 | — |
Chemo, chemotherapy; N/A, not available.
Ten patients out of 22 were treated with anthracycline-containing regimens.
Three patients out of 14 were treated with cyclophosphamide-doxorubicin-vincristine-prednisone and rituximab (or CHOP-R), and 11 out of 14 with cyclophosphamide-vincristine-prednisone and rituximab.
Forty-one patients out of 46 were treated with anthracycline-containing regimens.
Seventy-seven patients out of 82 were treated with CHOP-R.